1. Home
  2. SCYX vs IZM Comparison

SCYX vs IZM Comparison

Compare SCYX & IZM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • IZM
  • Stock Information
  • Founded
  • SCYX 1999
  • IZM 2011
  • Country
  • SCYX United States
  • IZM China
  • Employees
  • SCYX N/A
  • IZM N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • IZM Consumer Electronics/Video Chains
  • Sector
  • SCYX Health Care
  • IZM Consumer Discretionary
  • Exchange
  • SCYX Nasdaq
  • IZM Nasdaq
  • Market Cap
  • SCYX 28.5M
  • IZM 31.8M
  • IPO Year
  • SCYX 2014
  • IZM 2023
  • Fundamental
  • Price
  • SCYX $0.70
  • IZM $2.60
  • Analyst Decision
  • SCYX
  • IZM
  • Analyst Count
  • SCYX 0
  • IZM 0
  • Target Price
  • SCYX N/A
  • IZM N/A
  • AVG Volume (30 Days)
  • SCYX 187.5K
  • IZM 31.6K
  • Earning Date
  • SCYX 08-11-2025
  • IZM 08-05-2025
  • Dividend Yield
  • SCYX N/A
  • IZM N/A
  • EPS Growth
  • SCYX N/A
  • IZM N/A
  • EPS
  • SCYX N/A
  • IZM N/A
  • Revenue
  • SCYX $2,630,000.00
  • IZM $180,553,977.00
  • Revenue This Year
  • SCYX $410.22
  • IZM N/A
  • Revenue Next Year
  • SCYX $248.83
  • IZM N/A
  • P/E Ratio
  • SCYX N/A
  • IZM N/A
  • Revenue Growth
  • SCYX N/A
  • IZM N/A
  • 52 Week Low
  • SCYX $0.66
  • IZM $1.18
  • 52 Week High
  • SCYX $2.21
  • IZM $3.19
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 41.70
  • IZM 54.56
  • Support Level
  • SCYX $0.67
  • IZM $2.51
  • Resistance Level
  • SCYX $0.74
  • IZM $2.74
  • Average True Range (ATR)
  • SCYX 0.04
  • IZM 0.08
  • MACD
  • SCYX 0.00
  • IZM -0.00
  • Stochastic Oscillator
  • SCYX 10.15
  • IZM 58.82

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About IZM ICZOOM Group Inc.

ICZOOM Group Inc is engaged in the sale of electronic component products to customers in China. These products are used by small and medium-sized enterprises (SMEs) in the consumer electronic industry, Internet of Things (IoT), automotive electronics, and industrial control segment. In addition to the sales of electronic component products, also provides services to customers such as temporary warehousing, logistic and shipping, and customs clearance and charges them additional service commission fees. The company earns maximum revenue from sale of electronic components.

Share on Social Networks: